Moisan et al. reported C1142 (a mouse CCL2 inhibitor) combined with carboplatin in the treatment of ovarian cancer mouse model could improve the efficacy of carboplatin (Moisan et al., 2014). This evidence concerns the gene CCL2 and ovarian cancer.